Bright Light Therapy in the Morning or at Mid-Day in the Treatment of Non-Seasonal Bipolar Depressive Episodes (LuBi): Study Protocol for a Dose Research Phase I / II Trial
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective This study protocol aims to determine, using a rigorous approach in patients with bipolar disorder (BD) and non-seasonal major depressive episode (MDE), the characteristics of bright light therapy (BLT) administration (duration, escalation, morning and mid-day exposures) depending on the tolerance (hypomanic symptoms). Methods Patients with BD I or II and treated by a mood stabilizer are eligible. After 1 week of placebo, patients are randomized between either morning or mid-day exposure for 10 weeks of active BLT with glasses using a dose escalation at 7.5, 10, 15, 30 and 45 minutes/ day. A further follow-up visit is planned 6 months after inclusion. Patients will be included by cohorts of 3, with at least 3 days of delay between them, and 1 week between cohorts. If none meet a dose limiting toxicity (DLT; i.e hypomanic symptoms), the initiation dose of the next cohort will be increased. If one patient meet a DLT, an additionnal cohort will start at the same dose. If 2 or 3 patients meet a DLT, from the same cohort or from two cohorts at the same dose initiation, the maximum tolerated dose is defined. This dose escalation will also take into account DLTs observed during the intra-subject escalation on previous cohorts, with a “Target Ceiling Dose” defined if 2 DLTs occured at a dose. Discussion Using an innovative and more ergonomic device in the form of glasses, this study aims to better codify the use of BLT in BD to ensure a good initiation and tolerance.
Abstract
Objective This study protocol aims to determine, using a rigorous approach in patients with bipolar disorder (BD) and non-seasonal major depressive episode (MDE), the characteristics of bright light therapy (BLT) administration (duration, escalation, morning and mid-day exposures) depending on the tolerance (hypomanic symptoms). Methods Patients with BD I or II and treated by a mood stabilizer are eligible. After 1 week of placebo, patients are randomized between either morning or mid-day exposure for 10 weeks of active BLT with glasses using a dose escalation at 7.5, 10, 15, 30 and 45 minutes/ day. A further follow-up visit is planned 6 months after inclusion. Patients will be included by cohorts of 3, with at least 3 days of delay between them, and 1 week between cohorts. If none meet a dose limiting toxicity (DLT; i.e hypomanic symptoms), the initiation dose of the next cohort will be increased. If one patient meet a DLT, an additionnal cohort will start at the same dose. If 2 or 3 patients meet a DLT, from the same cohort or from two cohorts at the same dose initiation, the maximum tolerated dose is defined. This dose escalation will also take into account DLTs observed during the intra-subject escalation on previous cohorts, with a “Target Ceiling Dose” defined if 2 DLTs occured at a dose. Discussion Using an innovative and more ergonomic device in the form of glasses, this study aims to better codify the use of BLT in BD to ensure a good initiation and tolerance.
참고문헌 (55)
- Collins PY, "Grand challenges in global mental health", Nature, 475, pp.27~30 (2011)
- Merikangas KR, "Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication", Arch Gen Psychiatry, 64, pp.543~552 (2007)
- Chesney E, "Risks of all-cause and suicide mortality in mental disorders: a meta-review", World Psychiatry, 13, pp.153~160 (2014)
- Hayes JF, "A systematic review and meta-analysis of premature mortality in bipolar affective disorder", Acta Psychiatr Scand, 131, pp.417~425 (2015)
- Geddes JR, "Treatment of bipolar disorder", Lancet, 381, pp.1672~1682 (2013)
- Judd LL, "Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse", recurrence, 2008, pp.65, 386~394
- Tohen M, "Bowden CL, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone", Br J Psychiatry J Ment Sci, 184, pp.337~345 (2004)
- Judd LL, "The long-term natural history of the weekly symptomatic status of bipolar I disorder", Arch Gen Psychiatry, 59, pp.530~537 (2002)
- Judd LL, "A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder", Arch Gen Psychiatry, 60, pp.261~269 (2003)
- Judd LL, "Long-term symptomatic status of bipolar I vs. bipolar II disorders", Int J Neuropsychopharmacol, 6, pp.127~137 (2003)
- Grunze H, "The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders:update 2012 on the long-term treatment of bipolar disorder", World J Biol Psychiatry, 14, pp.154~219 (2013)
- Vieta E, "Treatment options for bipolar depression: a systematic review of randomized, controlled trials", J Clin Psychopharmacol, 30, pp.579~590 (2010)
- Geoffroy PA, "Light treatment in depression:An antique treatment with new insights", Sleep Med Rev, 40, pp.218~219 (2018)
- Geoffroy PA, "Bright light therapy in seasonal bipolar depressions", L’Encéphale, 41, pp.527~533 (2015)
- Rosenthal NE, "Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy", Arch Gen Psychiatry, 41, pp.72~80 (1984)
- Gross F, "Phototherapy in psychiatry: clinical update and review of indications", L’Encéphale, 22, pp.143~148 (1996)
- Sartori S, "Seasonal affective syndrome and phototherapy:theoretical concepts and clinical applications", L’Encéphale, 22, pp.7~16 (1996)
- Nussbaumer B, "Light therapy for preventing seasonal affective disorder", Cochrane Database Syst Rev, 11 (2015)
- Golden RN, "The efficacy of light therapy in the treatment of mood disorders:a review and meta-analysis of the evidence", Am J Psychiatry, 162, pp.656~662 (2005)
- Tseng PT, "Light therapy in the treatment of patients with bipolar depression: a metaanalytic study", Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol, 26, pp.1037~1047 (2016)
- Lam RW, "Morehouse R, et al. Efficacy of bright light treatment, fluoxetine, and the combination in patients with nonseasonal major depressive disorder: a randomized clinical trial", JAMA Psychiatry, 73, pp.56~63 (2016)
- Al-Karawi D, "Bright light therapy for nonseasonal depression:meta-analysis of clinical trials", J Affect Disord, 198, pp.64~71 (2016)
- Dauphinais DR, "Controlled trial of safety and efficacy of bright light therapy vs. negative air ions in patients with bipolar depression", Psychiatry Res, 196, pp.57~61 (2012)
- Kripke DF, "Controlled trial of bright light for nonseasonal major depressive disorders", Biol Psychiatry, 31, pp.119~134 (1992)
- Deltito JA, "Effects of phototherapy on non-seasonal unipolar and bipolar depressive spectrum disorders", J Affect Disord, 23, pp.231~237 (1991)
- Benedetti F., "Rate of switch from bipolar depression into mania after morning light therapy: A historical review", Psychiatry Res, 261, pp.351~356 (2018)
- Sit D, "Light therapy for bipolar disorder: a case series in women", Bipolar Disord, 9, pp.918~927 (2007)
- Sit DK, "Adjunctive bright light therapy for bipolar depression: a randomized double-blind placebo-controlled trial", Am J Psychiatry, 175, pp.131~139 (2018)
- Langevin RH, "Évaluation préliminaire de l’efficacitéde la Luminette® chez des adolescents atteints du syndrome de retard de phase du sommeil (SRPS)?: essai randomisé en simple insu et contrôlépar placebo", Médecine Sommeil, 11, pp.91~97 (2014)
- Meesters Y, "Low-intensity blue-enriched white light (750 lux) and standard bright light (10,000 lux) are equally effective in treating SAD. A randomized controlled study", BMC Psychiatry, 11, pp.17~ (2011)
- Simon R, "Accelerated titration designs for phase I clinical trials in oncology", J Natl Cancer Inst, 89, pp.1138~1147 (1997)
- Medioni J, "Innovative design for a phase 1 trial with intra-patient dose escalation: The Crotoxin study", Contemp Clin Trials Commun, 7, pp.186~188 (2017)
- First MB, "The Encyclopedia of Clinical Psychology" (2014), John Wiley & Sons, Inc
- Sheiner LB, "Study designs for dose-ranging", Clin Pharmacol Ther, 46, pp.63~77 (1989)
- Burgess HJ, "Bright light, dark and melatonin can promote circadian adaptation in night shift workers", Sleep Med Rev, 6, pp.407~420 (2002)
- Duffy JF, "Effect of light on human circadian physiology", Sleep Med Clin, 4, pp.165~177 (2009)
- Fahey CD, "Circadian rhythm sleep disorders and phototherapy", Psychiatr Clin, 29, pp.989~1007 (2006)
- Terman M, "Bright light therapy: side effects and benefits across the symptom spectrum", J Clin Psychiatry, 60, pp.799~808 (1999)
- van Maanen A, "The effects of light therapy on sleep problems: a systematic review and meta-analysis", Sleep Med Rev, 29, pp.52~62 (2015)
- Bellivier F, "Sleep- and circadian rhythmassociated pathways as therapeutic targets in bipolar disorder", Expert Opin Ther Targets, 19, pp.747~763 (2015)
- Geoffroy PA, "Sleep in remitted bipolar disorder: a naturalistic case-control study using actigraphy", J Affect Disord, 158, pp.1~7 (2014)
- Germain A, "Circadian rhythm disturbances in depression", Hum Psychopharmacol, 23, pp.571~585 (2008)
- Harvey AG, "Treating insomnia improves mood state, sleep, and functioning in bipolar disorder: a pilot randomized controlled trial", J Consult Clin Psychol, 83, pp.564~577 (2015)
- McClung CA, "How might circadian rhythms control mood? Let me count the ways", Biol Psychiatry, 74, pp.242~249 (2013)
- Milhiet V, "Circadian abnormalities as markers of susceptibility in bipolar disorders", Front Biosci (Schol Ed), 6, pp.120~137 (2014)
- Pillai V, "A Meta-Analysis of Electroencephalographic Sleep in Depression: Evidence for Genetic Biomarkers", Biol Psychiatry, 70, pp.912~919 (2011)
- Terman M, "Light therapy for seasonal and nonseasonal depression:efficacy, protocol, safety, and side effects", CNS Spectr, 10, pp.647~663 (2005)
- Leibenluft E, "Light therapy in patients with rapid cycling bipolar disorder:preliminary results", Psychopharmacol Bull, 31, pp.705~710 (1995)
- Levitt AJ, "Side effects of light therapy in seasonal affective disorder", Am J Psychiatry, 150, pp.650~652 (1993)
- Labbate LA, "Side effects induced by bright light treatment for seasonal affective disorder", J Clin Psychiatry, 55, pp.189~191 (1994)
- Gallin PF, "Ophthalmologic examination of patients with seasonal affective disorder, before and after bright light therapy", Am J Ophthalmol, 119, pp.202~210 (1995)
- Praschak-Rieder N, "Suicidal tendencies as a complication of light therapy for seasonal affective disorder: a report of three cases", J Clin Psychiatry, 58, pp.389~392 (1997)
- Lam RW, "Effects of light therapy on suicidal ideation in patients with winter depression", J Clin Psychiatry, 61, pp.30~32 (2000)
- Sahlem GL, "Adjunctive triple chronotherapy (combined total sleep deprivation, sleep phase advance, and bright light therapy) rapidly improves mood and suicidality in suicidal depressed inpatients: an open label pilot study", J Psychiatr Res, 59, pp.101~107 (2014)
- Benedetti F, "Rapid treatment response of suicidal symptoms to lithium, sleep deprivation, and light therapy (chronotherapeutics) in drug-resistant bipolar depression", J Clin Psychiatry, 75, pp.133~140 (2014)